Trilobatin ameliorates HFD/STZ-induced glycolipid metabolism disorders through AMPK-mediated pathways

Lithocarpus polystachyus Rehd is a sweet tea passed down from the folklore of southern China and is said to be effective in emaciation-thirst disease, which traditional Chinese medicine considers as diabetes. In the present study, we purified the major dihydrochalcone compound trilobatin (TRI) from sweet tea. Besides, a high-fat diet (HFD) combined with streptozotocin (STZ) induced type 2 diabetic mice model was used to investigate the effect of TRI in preventing glycolipid metabolism disorder. According to the results, TRI administration provided some improvement in elevated blood lipids, liver function, fatty liver, glucose metabolism disorders, and insulin sensitivity. These results demonstrated that TRI suppresses glycolipid metabolism disorder. According to the western blotting results, TRI stimulates AMPK and ACC phosphorylation while inhibiting the production of PGC1 alpha, PCK1, and G6Pase. Thus, AMPK-mediated gluconeogenesis and fatty acid anabolism may be inhibited by TRI, which may be the mechanism that TRI ameliorates glycolipid metabolism disorder.

Automated summary

In this study, the major dihydrochalcone compound trilobatin (TRI) was purified from sweet tea and its effect in preventing glycolipid metabolism disorder was investigated using a type 2 diabetic mice model induced by a high-fat diet (HFD) combined with streptozotocin (STZ). The results showed that TRI administration improved elevated blood lipids, liver function, fatty liver, glucose metabolism disorders, and insulin sensitivity. Additionally, TRI was found to inhibit AMPK-mediated gluconeogenesis and fatty acid anabolism, suggesting its mechanism in ameliorating glycolipid metabolism disorder.